August 16, 2018
WELLESLEY, Mass., Aug.16, 2018–Increasing acceptance of endovascular procedures and increasing diagnosis of aortic aneurysms worldwide are two factors helping to drive the endovascular treatment devices market, according to a report by BCC Research.
The industry expects to see a compound annual growth rate (CAGR) of 7.3% through 2022, when it could be worth more than $2.8 billion, as outlined in the report Endovascular Treatment Devices: EVAR and TEVAR Emphasis.
Major players in the market mentioned in this report include Altura Medical, BiFlow Medical, Boston Scientific, Cardinal Health, Endologix, Endospan, Getinge, InspireMD, Japan Lifeline, Lifetech Scientific, Lombard Medical Technologies, Medtronic, Nellix, Penumbra and Terumo.
“Endovascular treatment (e.g., EVAR, TEVAR) has created a great buzz in the last decade due to its advantages over open surgical repair,” said BCC Research analyst and report author Dr. Ritu Thakur Dangi. “The U.S. leads the market of both segments, followed by Europe, Asia and ROW. Although Asia is growing fast, the U.S. will continue to have the largest share in the global aortic stent graft market through 2022. TAA is a relatively new and niche segment globally, but it is growing and has a strong growth potential for the future due to a strong pipeline of products from early-stage start-ups and established players.”
Growing Geriatric Population Expected to Drive Global Market
The worldwide increase in the geriatric population is helping to drive the market, the report adds, as elderly people are at a higher risk of acquiring various diseases. In the United States, average life expectancy will increase from 77.8 years in 2005 to 79.8 years in 2020, while in Europe the population 65 and older will increase at a CAGR of 1.6% between 2010 and 2030, from 121 million to 165 million. The story is similar in Japan, where the population age 65 and older will increase from 29 million in 2010 to 37 million by 2030.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Endovascular Treatment Devices: EVAR and TEVAR Emphasis( HLC203A )
Publish Date: Aug 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.